The authors report no conflicts of interest.
EFFECTS OF ARIPIPRAZOLE AUGMENTATION IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER (A DOUBLE BLIND CLINICAL TRIAL)
Article first published online: 29 AUG 2012
© 2012 Wiley Periodicals, Inc.
Depression and Anxiety
Volume 29, Issue 10, pages 850–854, October 2012
How to Cite
Sayyah, M., Sayyah, M., Boostani, H., Ghaffari, S. M. and Hoseini, A. (2012), EFFECTS OF ARIPIPRAZOLE AUGMENTATION IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER (A DOUBLE BLIND CLINICAL TRIAL). Depress. Anxiety, 29: 850–854. doi: 10.1002/da.21996
- Issue published online: 1 OCT 2012
- Article first published online: 29 AUG 2012
- Manuscript Accepted: 9 AUG 2012
- Manuscript Revised: 31 JUL 2012
- Manuscript Received: 15 JAN 2012
- clinical trial;
- OCD/obsessive-compulsive disorder;
- treatment resistance;
- sexual dysfunction
Obsessive-compulsive disorder (OCD) is a chronic disorder with unknown etiology. Failure in OCD treatmentcompulsive is common and finding effective augmentations in treatment of OCD will benefit patients. Antipsychotic augmentation is a common strategy for treatment resistant OCD. This trial evaluated the efficacy of adding aripiprazole in patients whose OCD was insufficiently responsive to an adequate SSRI treatment.
Thirty-nine adult outpatients, who met the DSM-IV-TR criteria for OCD and had treatment resistant OCD were evaluated in a double-blind randomized clinical trial. The patients received either aripiprazole 10 mg/day or placebo, for 12 weeks. Data were analyzed using intention-to-treat analysis with last observation carried forward. All statistical tests were two-sided, and were considered statistically significant at P < 0.05.
A significant reduction in total scores of Y-BOCS (P < 0.0001) was found in the aripiprazole group. Aripiprazole was generally well tolerated. There was no significant difference between the two groups in terms of observed side effects.
Results of the present study indicate that aripiprazole could be an effective augmentation medicine in treatment resistant OCD.